Business
BioRestorative Therapies Reports First Quarter 2025 Financial Results and Provides Business Update
MELVILLE, N.Y., May 14, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, today reported financial results for the first quarter ended March 31, 2025 and provided an update on its business. “We have continued to execute well across our business, including the achievement of key clinical program milestones, since the start of 2025,” said Lance Alsto
About this update from Biorestorative Therapies, Inc.
[{"type":"image","alt":"BioRestorative Therapies, Inc","displaySize":"","headline":null,"caption":"BioRestorative Therapies, Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":122,"url":"https://media.zenfs.com/en/globenewswire.com/681a8d8fe6df06a5512b4bdd3f27c992"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/XBsy.n130Az83pQRRSvCjg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE3MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/681a8d8fe6df06a5512b4bdd3f27c992","width":300,"height":122}},"lazy":false},{"type":"text","content":"MELVILLE, N.Y., May 14, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, today reported financial results for the first quarter ended March 31, 2025 and provided an update on its business.","length":339,"tagName":"p"},{"type":"text","content":"“We have continued to execute well across our business, including the achievement of key clinical program milestones, since the start of 2025,” said Lance Alstodt, the Company’s Chief Executive Officer. “Moving forward, we remain focused on aggressively executing our growth strategy while carefully managing our resources, and we see many potential value enhancing inflection points ahead.”","length":391,"tagName":"p"},{"type":"text","content":"Recent Highlights","length":17,"tagName":"p"},{"type":"text","content":"Corporate","length":9,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"In April, the Company confirmed that it currently faces no material exposure to newly imposed U.S. tariffs. BioRestorative believes that its ‘made-in-America’ production and manufacturing strategy, combined with its use of domestic inputs, enables it to effectively manage costs amid global supply chain shifts.","length":311,"tagName":"p"}]},{"val":[{"type":"text","content":"Also in April, BioRestorative’s Chief Executive Officer, Lance Alstodt, was interviewed during the Benzinga All-Access Show. An archive of the interview can be accessed here.","length":174,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":485,"olType":false},{"type":"text","content":"Disc/Spine Program ","length":18,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"In a February podium presentati...